- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07739550
Low-Intensity Shock Wave Therapy for Refractory Overactive Bladder in Women
Therapeutic Effects of Low-Intensity Extracorporeal Shock Wave Therapy on Refractory Overactive Bladder Symptoms in Females
Overactive bladder is a condition characterized by a sudden and difficult-to-control need to urinate, which may occur with frequent urination, nighttime urination, and urine leakage. Some women continue to experience these symptoms despite lifestyle changes, behavioral therapy, and medication, or they cannot tolerate or decline medical treatment.
This study will evaluate whether low-intensity extracorporeal shock wave therapy (Li-ESWT), a non-surgical treatment delivered externally over the lower abdomen, can safely improve refractory overactive bladder symptoms in women.
A total of 40 women will be randomly assigned in equal numbers to receive either active Li-ESWT or a sham treatment. Both groups will attend one treatment session each week for six weeks. The sham procedure will be similar to the active treatment in positioning, session duration, and device sound but will not deliver shock wave energy.
Symptoms will be assessed using the validated Arabic version of the 8-item Overactive Bladder Questionnaire (OAB-V8) before treatment and during follow-up. The main purpose of the study is to compare the change in OAB-V8 symptom score between the two groups after one month. Additional assessments at three months will include post-void residual urine volume, information from a 3-day voiding diary, the participant's overall impression of improvement, and any treatment-related adverse events.
The study hypothesis is that Li-ESWT will improve overactive bladder symptoms and quality of life compared with sham treatment.
Обзор исследования
Статус
Условия
Тип исследования
Регистрация (Оцененный)
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
- Имя: Abdelrahman F Senosy, MBBCh
- Номер телефона: +02 010 95324741
- Электронная почта: Abdelrahmanadam96@gmail.com
Места учебы
-
-
Cairo Governorate
-
Cairo, Cairo Governorate, Египет, 11511
- Ain Shams University Hospital
-
Контакт:
- Abdelrahman F Senosy, MBBCh
- Номер телефона: +2 010 95324741
- Электронная почта: Abdelrahmanadam96@gmail.com
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
- Взрослый
- Пожилой взрослый
Принимает здоровых добровольцев
Описание
Inclusion Criteria:
- Female participants aged 18 to 70 years.
- Symptoms of overactive bladder with an Overactive Bladder Questionnaire 8-Item total score greater than 8.
- Failure of behavioral therapy and medical treatment for overactive bladder.
- Refusal of medical treatment for overactive bladder. Ability to understand the study procedures and provide written informed consent.
Exclusion Criteria:
- Current use of medical treatment for overactive bladder.
- Cardiac pacemaker or metallic implant in the treatment area.
- Coagulation disorder or use of anticoagulants that cannot be temporarily discontinued.
- Active urinary tract infection; participants may be reconsidered after successful treatment and recovery.
- Urinary bladder stones.
- Post-void residual urine volume greater than 100 mL.
- Lower urinary tract surgery within the previous 6 months.
- Previous pelvic radiation therapy.
- History of neuropathic disease.
- Pregnancy or planning to become pregnant.
- Hepatic, renal, or cardiac impairment.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Двойной
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Active Low-Intensity Extracorporeal Shock Wave Therapy
Participants will receive active low-intensity extracorporeal shock wave therapy using the PiezoWave 2 focused extracorporeal shock wave therapy device.
Treatment will be administered once weekly for 6 weeks.
Before each session, participants will drink 1000 mL of water, and treatment will begin when the bladder reaches approximately 50% of the participant's functional bladder capacity, confirmed by bladder scan.
The probe will be placed over the lower abdomen approximately two fingerbreadths above the pubic symphysis and directed toward the bladder dome and bilateral bladder walls.
Each session will deliver 1000 impulses to each target area, for a total of 3000 impulses, at an energy density of 0.25 mJ/mm² and a frequency of 3 pulses per second.
|
Focused low-intensity extracorporeal shock wave therapy will be delivered using the PiezoWave 2 device.
Each session will deliver a total of 3000 impulses at an energy density of 0.25 mJ/mm² and a frequency of 3 pulses per second.
Treatment will be administered once weekly for 6 weeks.
|
|
Фальшивый компаратор: Sham Low-Intensity Extracorporeal Shock Wave Therapy
Participants will receive a sham procedure once weekly for 6 weeks.
The procedure will be similar to the active treatment in participant positioning, bladder preparation, probe placement, session duration, and device sound.
A sham probe or zero-energy device setting will be used so that no therapeutic shock wave energy is delivered.
|
A sham procedure will be administered using the same treatment setup, participant positioning, probe placement, session duration, and device sound as active therapy.
A sham probe or zero-energy setting will be used so that no therapeutic shock wave energy is delivered.
The procedure will be performed once weekly for 6 weeks.
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Overactive Bladder Questionnaire 8-Item Total Score
Временное ограничение: Baseline and 1 month after completion of the 6-week treatment
|
The Arabic-validated Overactive Bladder Questionnaire 8-Item (OAB-V8) will be completed at baseline and 1 month after completion of treatment.
The questionnaire contains 8 items scored from 0 to 5, giving a total score ranging from 0 to 40.
Higher scores indicate greater symptom-related bother.
The outcome will be calculated as the change in total OAB-V8 score from baseline to the 1-month assessment.
|
Baseline and 1 month after completion of the 6-week treatment
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Post-Void Residual Urine Volume at 3 Months
Временное ограничение: Baseline and 3 months after completion of treatment
|
Post-void residual urine volume will be measured by ultrasound after urination and recorded in milliliters.
The outcome will be calculated as the change from baseline to the 3-month follow-up assessment.
|
Baseline and 3 months after completion of treatment
|
|
Urinary Frequency Recorded in a 3-Day Voiding Diary
Временное ограничение: Baseline and 3 months after completion of treatment
|
Participants will record the timing and number of urination episodes in a 3-day voiding diary.
The outcome will assess the change in urinary frequency from baseline to the 3-month follow-up assessment.
|
Baseline and 3 months after completion of treatment
|
|
Mean Voided Urine Volume Recorded in a 3-Day Voiding Diary
Временное ограничение: Baseline and 3 months after completion of treatment
|
The volume of urine passed during each urination will be recorded in milliliters in a 3-day voiding diary.
Mean voided volume will be calculated, and the change from baseline to the 3-month follow-up assessment will be evaluated.
|
Baseline and 3 months after completion of treatment
|
|
Urgency Level Recorded in a 3-Day Voiding Diary
Временное ограничение: Baseline and 3 months after completion of treatment
|
Participants will record the level of urinary urgency associated with each urination episode in a 3-day voiding diary.
The outcome will assess the change in recorded urgency level from baseline to the 3-month follow-up assessment.
|
Baseline and 3 months after completion of treatment
|
|
Urinary Leakage Episodes Recorded in a 3-Day Voiding Diary
Временное ограничение: Baseline and 3 months after completion of treatment
|
The number of involuntary urinary leakage episodes will be recorded over 3 consecutive days.
The outcome will be calculated as the change in the number of leakage episodes from baseline to the 3-month follow-up assessment.
|
Baseline and 3 months after completion of treatment
|
|
Functional Bladder Capacity
Временное ограничение: Baseline and 3 months after completion of treatment
|
Functional bladder capacity will be derived from measurements recorded in the participant's 3-day voiding diary and expressed in milliliters.
The outcome will assess the change from baseline to the 3-month follow-up assessment.
|
Baseline and 3 months after completion of treatment
|
Соавторы и исследователи
Спонсор
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
- Ургентное недержание мочи
- Никтурия
- Мочевая срочность
- Частое мочеиспускание
- Низкоинтенсивная экстракорпоральная ударно-волновая терапия
- Рефрактерный гиперактивный мочевой пузырь
- Female Lower Urinary Tract Symptoms
- Functional Bladder Capacity
- Post-Void Residual Urine
- Sham-Controlled Clinical Trial
- Overactive Bladder Questionnaire, 8-Item
Дополнительные соответствующие термины MeSH
- Урогенитальные заболевания
- Мужские мочеполовые заболевания
- Урологические заболевания
- Женские урогенитальные заболевания
- Женские мочеполовые заболевания и осложнения беременности
- Симптомы нижних мочевыводящих путей
- Урологические проявления
- Заболевания мочевого пузыря
- Патологические состояния, признаки и симптомы
- Признаки и симптомы
- Мочевой пузырь, гиперактивность
- Никтурия
Другие идентификационные номера исследования
- FMASU MS 434/2026
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .